Skip to main content
. 2016 Feb 10;11(2):e0148657. doi: 10.1371/journal.pone.0148657

Fig 3. SB204741 reduces SRC phosphorylation and downstream activation through reduction of motility of SRC.

Fig 3

(A) Western blots from BMPR2 mutant or WT mice whole lung treated with SB204741 or vehicle. BMPR2 mutants show increased phosphorylation of SRC target CAS; SRC activity and phosphorylation is reduced with SB204741 treatment. (B) Densitometry for pSRC, pCAS, and pCAV1 phosphorylation. Values are normalized to total protein and β-actin (i.e. pSRC/SRC/β-actin). n = 3, *p<0.05 compared to WT, #p<0.05 compared to vehicle treated.